1. The PI3K/AKT/mTOR and CDK4/6 Pathways in Endocrine Resistant HR+/HER2− Metastatic Breast Cancer: Biological Mechanisms and New Treatments
   Daniele Presti et al, 2019, Cancers CrossRef
2. Emerging Roles for Mammalian Target of Rapamycin (mTOR) Complexes in Bladder Cancer Progression and Therapy
   Jianya Huan et al, 2022, Cancers CrossRef
3. ONC201/TIC10 enhances durability of mTOR inhibitor everolimus in metastatic ER+ breast cancer
   Elena Farmaki et al, 2023, eLife CrossRef
4. The SMAC mimetic GDC-0152 is a direct ABCB1-ATPase activity modulator and BIRC5 expression suppressor in cancer cells
   I-Li Lin et al, 2024, Toxicology and Applied Pharmacology CrossRef
5. Autophagy Modulators: Mechanistic Aspects and Drug Delivery Systems
   Shima Tavakol et al, 2019, Biomolecules CrossRef
6. Growth inhibitory efficacy and anti‑aromatase activity of Tabebuia avellanedae in a model for post‑menopausal Luminal A breast cancer
   Nitin Telang et al, 2019, Biomedical Reports CrossRef
7. Luminal A breast cancer resistance mechanisms and emerging treatments
   Deborah H. Anderson, 2021, Biological Mechanisms and the Advancing Approaches to Overcoming Cancer Drug Resistance CrossRef
8. In Vitro Effects of Combining Genistein with Aromatase Inhibitors: Concerns Regarding Its Consumption during Breast Cancer Treatment
   Patrícia H. A. Bezerra et al, 2023, Molecules CrossRef
9. Guidelines for the role of autophagy in drug delivery vectors uptake pathways
   Moataz Dowaidar, 2024, Heliyon CrossRef